Danazol causes significant changes in the cardiometabolic profile of patients with acquired aplastic anaemia

Hitesh Gurjar; Ankur Jain; Sujata Wangkheimayum; Subhash Varma; Rajesh Vijayvergiya; Pankaj Malhotra

doi:10.1016/j.bcmd.2025.102921

Danazol causes significant changes in the cardiometabolic profile of patients with acquired aplastic anaemia

Hitesh Gurjar, Ankur Jain, Sujata Wangkheimayum, Subhash Varma, Rajesh Vijayvergiya, Pankaj Malhotra

In: Blood Cells, Molecules, and Diseases · 2025 · vol. 112 , pp. 102921 · doi:10.1016/j.bcmd.2025.102921 · PMID:40174329 · W4408933636

article OA: closed CC0

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (39)

Action of danazol on plasma lipids and lipoprotein metabolism. via openalex
Danazol and plasma lipoprotein metabolism via openalex
Danazol increases T regulatory cells in patients with aplastic anemia via openalex
Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid via openalex
doi:10.1016/j.jaci.2004.12.1130 via openalex
doi:10.1016/0002-9149(86)90771-x via openalex
doi:10.1177/0960327109104821 via openalex
W2283333399 via openalex
W2409042624 via openalex
doi:10.1007/bf00418510 via openalex
doi:10.1016/0002-9149(86)90392-9 via openalex
doi:10.1093/ehjci/jex244 via openalex
doi:10.1136/bjsm.2006.030171 via openalex
doi:10.1111/j.1559-4564.2006.05210.x via openalex
doi:10.1016/j.echo.2014.10.003 via openalex
doi:10.1002/j.1552-4604.1996.tb04167.x via openalex
doi:10.15420/cfr.2015.1.2.87 via openalex
doi:10.1016/j.amjcard.2005.10.026 via openalex
doi:10.1016/j.jjcc.2019.03.002 via openalex
doi:10.3389/fonc.2023.1135160 via openalex
doi:10.3390/jcm11237152 via openalex
doi:10.1155/2020/3106012 via openalex
doi:10.1186/s44156-024-00051-2 via openalex
W6695845664 via openalex
W6714444516 via openalex
W6715458637 via openalex
W6779883391 via openalex
W6852098804 via openalex
doi:10.1016/s0002-8703(03)00322-3 via openalex
doi:10.1016/j.ijcard.2007.12.027 via openalex
doi:10.1007/s00059-006-2856-0 via openalex
doi:10.1016/j.bcmd.2024.102857 via openalex
doi:10.1016/0735-1097(92)90478-6 via openalex
doi:10.1016/j.echo.2018.11.011 via openalex
doi:10.1016/j.ihj.2014.03.005 via openalex
doi:10.1016/j.echo.2008.11.023 via openalex
doi:10.1179/1607845414y.0000000196 via openalex
doi:10.1016/s0735-1097(97)00344-6 via openalex
doi:10.1016/j.atherosclerosis.2007.09.025 via openalex

Source provenance

openalex: last seen: 2026-05-11T06:58:58.389534+00:00
unpaywall: last seen: 2026-06-02T02:00:03.124865+00:00

License: CC0 · commercial use OK

[1] Action of danazol on plasma lipids and lipoprotein metabolism. 1994

[2] Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid 1992

[3] Danazol increases T regulatory cells in patients with aplastic anemia 2018

[4] Danazol and plasma lipoprotein metabolism 1995